Filter:
Able AI
What's the best dilution for OBSCN in ?
Tested Applications
| Positive IHC detected in | human skeletal muscle tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
55281-1-AP targets OBSCN in IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
| Calculated Molecular Weight | 925 kDa |
| GenBank Accession Number | NM_052843 |
| Gene Symbol | OBSCN |
| Gene ID (NCBI) | 84033 |
| RRID | AB_2881297 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q5VST9 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for OBSCN antibody 55281-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The OBSCN Polyclonal antibody (Cat# 55281-1-AP) has 1 total citation. It appears in Cell Bioscience (IF 6.5), published in 2025. The cited study investigated bladder cancer progression and PD-L1 inhibitor efficacy, placing this citation in the fields of oncology and immunotherapy. The application used was IHC.
| Species | Application | Title |
|---|---|---|
Cell Biosci Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors |
